title: Neurotrophic effects of progranulin in vivo in reversing motor neuron defects caused by over or under expression of TDP-43 or FUS.
abstract: Progranulin (PGRN) is a glycoprotein with multiple roles in normal and disease states. Mutations within the GRN gene cause frontotemporal lobar degeneration (FTLD). The affected neurons display distinctive TAR DNA binding protein 43 (TDP-43) inclusions. How partial loss of PGRN causes TDP-43 neuropathology is poorly understood. TDP-43 inclusions are also found in affected neurons of patients with other neurodegenerative diseases including amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. In ALS, TDP-43 inclusions are typically also immunoreactive for fused in sarcoma (FUS). Mutations within TDP-43 or FUS are themselves neuropathogenic in ALS and some cases of FTLD. We used the outgrowth of caudal primary motor neurons (MNs) in zebrafish embryos to investigate the interaction of PGRN with TDP-43 and FUS in vivo. As reported previously, depletion of zebrafish PGRN-A (zfPGRN-A) is associated with truncated primary MNs and impaired motor function. Here we found that depletion of zfPGRN-A results in primary MNs outgrowth stalling at the horizontal myoseptum, a line of demarcation separating the myotome into dorsal and ventral compartments that is where the final destination of primary motor is assigned. Successful axonal outgrowth beyond the horizontal myoseptum depends in part upon formation of acetylcholine receptor clusters and this was found to be disorganized upon depletion of zfPGRN-A. PGRN reversed the effects of zfPGRN-A knockdown, but a related gene, zfPGRN-1, was without effect. Both knockdown of TDP-43 or FUS, as well as expression of humanTDP-43 and FUS mutants results in MN abnormalities that are reversed by co-expression of hPGRN mRNA. Neither TDP-43 nor FUS reversed MN phenotypes caused by the depletion of PGRN. Thus TDP-43 and FUS lie upstream of PGRN in a gene complementation pathway. The ability of PGRN to override TDP-43 and FUS neurotoxicity due to partial loss of function or mutation in the corresponding genes may have therapeutic relevance.
authors.affiliation: Endocrine Research Laboratory, Royal Victoria Hospital, McGill University Health Centre Research Institute, Montreal, Québec, Canada.|Neurodyn Inc., Charlottetown, Prince Edward Island, Canada.
authors.forename: Babykumari P
authors.initials: BP
authors.lastname: Chitramuthu
authors.affiliation: Neurodyn Inc., Charlottetown, Prince Edward Island, Canada.
authors.forename: Denis G
authors.initials: DG
authors.lastname: Kay
authors.affiliation: Endocrine Research Laboratory, Royal Victoria Hospital, McGill University Health Centre Research Institute, Montreal, Québec, Canada.
authors.forename: Andrew
authors.initials: A
authors.lastname: Bateman
authors.affiliation: Endocrine Research Laboratory, Royal Victoria Hospital, McGill University Health Centre Research Institute, Montreal, Québec, Canada.
authors.forename: Hugh P J
authors.initials: HP
authors.lastname: Bennett
mesh_terms: D000818:Animals; D004268:DNA-Binding Proteins / Q000235:genetics / Q000378:metabolism*; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics / Q000378:metabolism*; D009046:Motor Neurons / Q000378:metabolism*; D009154:Mutation / Q000235:genetics; D034702:RNA-Binding Protein FUS / Q000235:genetics / Q000378:metabolism*; D015027:Zebrafish; D029961:Zebrafish Proteins / Q000235:genetics / Q000378:metabolism*
chemical_list: D004268:DNA-Binding Proteins; D036341:Intercellular Signaling Peptides and Proteins; D034702:RNA-Binding Protein FUS; C585345:Tardbp protein, zebrafish; D029961:Zebrafish Proteins